Nucleic acid molecule for specifically targeting HBV (Hepatitis B Virus) and expression cassette, expression vector and transformant of nucleic acid molecule
The invention provides a nucleic acid molecule for specifically targeting HBV and an expression cassette, an expression vector and a transformant thereof, the nucleic acid molecule comprises: (a) a nucleotide sequence for coding shRNA (short hairpin Ribonucleic Acid), as shown in SEQ ID NO.1; (b) a nucleotide sequence for coding the sgRNA1, wherein the nucleotide sequence is as shown in SEQ ID NO. 2; (c) a nucleotide sequence for coding sgRNA2, wherein the nucleotide sequence is as shown in SEQ ID NO. 3; and (d) a nucleotide sequence encoding Cas9; the shRNA, the sgRNA1, the sgRNA2 and the Cas9 are respectively positioned in four translation reading frames. The CRISPR/Cas9 system and the RNAi system are integrated on one expression vector, on one hand, the Cas9 protein and shRNA expression level in each cell can be ensured to be consistent, the expression efficiency of the four expression cassettes cannot be mutually influenced, and the highest expression level can be reached, so that the maximum inhibition efficiency on a target gene is achieved; on the other hand, the shRNA and the double-target CRISPR/Cas9 play a synergistic interaction role through respective unique mechanisms..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 18. Juli Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
MENG ZHONGJI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-07-18, Last update posted on www.tib.eu: 2023-11-28, Last updated: 2023-12-01 |
|---|
| Patentnummer: |
CN116445480 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018222250 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018222250 | ||
| 003 | DE-627 | ||
| 005 | 20231201094821.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231013s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018222250 | ||
| 035 | |a (EPA)CN116445480 | ||
| 035 | |a (EPA)87130806 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a MENG ZHONGJI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nucleic acid molecule for specifically targeting HBV (Hepatitis B Virus) and expression cassette, expression vector and transformant of nucleic acid molecule |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-07-18, Last update posted on www.tib.eu: 2023-11-28, Last updated: 2023-12-01 | ||
| 520 | |a The invention provides a nucleic acid molecule for specifically targeting HBV and an expression cassette, an expression vector and a transformant thereof, the nucleic acid molecule comprises: (a) a nucleotide sequence for coding shRNA (short hairpin Ribonucleic Acid), as shown in SEQ ID NO.1; (b) a nucleotide sequence for coding the sgRNA1, wherein the nucleotide sequence is as shown in SEQ ID NO. 2; (c) a nucleotide sequence for coding sgRNA2, wherein the nucleotide sequence is as shown in SEQ ID NO. 3; and (d) a nucleotide sequence encoding Cas9; the shRNA, the sgRNA1, the sgRNA2 and the Cas9 are respectively positioned in four translation reading frames. The CRISPR/Cas9 system and the RNAi system are integrated on one expression vector, on one hand, the Cas9 protein and shRNA expression level in each cell can be ensured to be consistent, the expression efficiency of the four expression cassettes cannot be mutually influenced, and the highest expression level can be reached, so that the maximum inhibition efficiency on a target gene is achieved; on the other hand, the shRNA and the double-target CRISPR/Cas9 play a synergistic interaction role through respective unique mechanisms. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a CHENG BIN |4 aut | |
| 700 | 0 | |a LAN TINGYU |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 18. Juli |
| 773 | 1 | 8 | |g year:2023 |g day:18 |g month:07 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/87130806/publication/CN116445480A1?q=CN116445480 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 18 |c 07 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 18 |c 07 | ||